The immunologic constant of rejection

Trends in Immunology

Volumn 29, Issue 6, 2008, Pages 256-262

  Wang, Ena ^a,b   Worschech, Andrea ^a,b,c   Marincola, Francesco M ^a,b  

^a CLINICAL CENTER   (United States)

^b GENELUX CORPORATION   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENETIC TRANSCRIPTION; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INNATE IMMUNITY; MULTIPLE ORGAN FAILURE; NONHUMAN; TISSUE INJURY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REJECTION;

ANIMALS; CHEMOKINES; CYTOTOXICITY, IMMUNOLOGIC; GRAFT REJECTION; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY; IMMUNOTHERAPY; INFECTION; INFLAMMATION; INTERFERON REGULATORY FACTORS; NEOPLASMS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; TOLL-LIKE RECEPTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 44549086338     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2008.03.002     Document Type: Article

References (74)

1. Mantovani A. Cancer: inflammation by remote control. Nature 435 (2005) 752-753
2. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
3. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315 (1986) 1650-1659
4. Salk J. Immunological paradoxes: theoretical considerations in the rejection or retention of grafts, tumors, and normal tissue. Ann. N. Y. Acad. Sci. 164 (1969) 365-380
5. Maker A.V., et al. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175 (2005) 7746-7754
6. Zinkernagel R.M. Localization dose and time of antigens determine immune reactivity. Semin. Immunol 12 (2000) 163-171
7. Matzinger P. Friendly and dangerous signals: is the tissue in control?. Nat. Immunol. 8 (2007) 11-13
8. Kawakami Y., et al. Tumor antigens recognized by T cells. The use of melanosomal proteins in the immunotherapy of melanoma. J. Immunother. 21 (1998) 237-246
9. Suri A. Cancer testis antigens-their importance in immunotherapy and in the early detection of cancer. Expert Opin. Biol. Ther. 6 (2006) 379-389
10. Andersen M.H., and Thor Straten P. Survivin - a universal tumor antigen. Histol. Histopathol. 17 (2002) 669-675
11. Robbins P.F., et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183 (1996) 1185-1192
12. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 (2005) 215-229
13. Sarwal M., et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med. 349 (2003) 125-138
14. Deola S., et al. "Helper" B cells promote cytotoxic T cell survival and proliferation indepdently of antigen presentation through CD27-CD70 interactions. J. Immunol. 180 (2008) 1362-1372
15. Old L.J., and Chen Y.T. New Paths in Human Cancer Serology. J. Exp. Med. 187 (1998) 1163-1167
16. Rosenberg S.A., and White D.E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphsis Tumor Immunol. 19 (1996) 81-84
17. Gogas H., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354 (2006) 709-718
18. Slingluff Jr. C.L., and Speiser D.E. Progress and controversies in developing cancer vaccines. J. Transl. Med. 3 (2005) 18
19. Dudley M.E., et al. Cancer regression and autoimmunity in patients after clonal repopulation wiht antitumor lymphocytes. Science 298 (2002) 850-854
20. Wolfel T., et al. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J. Exp. Med. 170 (1989) 797-810
21. Marincola F.M., et al. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J. Immunother. Emphasis Tumor Immunol. 19 (1996) 266-277
22. Lee K.-H., et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163 (1999) 6292-6300
23. Monsurrò V., et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 104 (2004) 1970-1978
24. Lee P.P., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5 (1999) 677-685
25. Stuge T.B., et al. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 1 (2004) e28
26. Kammula U.S., et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163 (1999) 6867-6879
27. Marincola F.M., et al. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74 (2000) 181-273
28. Marincola F.M., et al. Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol. 24 (2003) 335-342
29. Farci P., et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 (2000) 339-344
30. Karlsson A.C., et al. Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS. ONE 2 (2007) e225
31. Dunn G.P., et al. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22 (2004) 329-360
32. Mantovani A., et al. Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 371 (2008) 771-783
33. Panelli M.C., et al. Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol. 8 (2007) R8
34. Urosevic M., et al. Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas. J. Clin. Invest. 117 (2007) 2834-2846
35. Atkins M.B., et al. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer Res. 10 (2004) 6342S-6346S
36. Hicks A.M., et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7753-7758
37. Rees J. Complex disease and the new clinical sciences. Science 296 (2002) 698-700
38. Panelli M.C., et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 3 (2002) RESEARCH0035
39. Wang E., et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62 (2002) 3581-3586
40. Monsurrò V., et al. Active-specific immunization against melanoma: is the problem at the receiving end?. Semin. Cancer Biol. 13 (2003) 473-480
41. Deonarine K., et al. Gene expression profiling of cutaneous wound healing. J. Transl. Med. 5 (2007) 11
42. Liu C., et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat. Med. 13 (2007) 1295-1298
43. Steinmetz O.M., et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 84 (2007) 842-850
44. Celik A., et al. Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report. Transplant. Proc. 40 (2008) 302-304
45. Ruiz-Arguelles G.J., et al. Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 14 (2008) 7-9
46. He X.S., et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44 (2006) 352-359
47. Wang E., et al. Melanoma-restricted genes. J. Transl. Med. 2 (2004) 34
48. Mandruzzato S., et al. A gene expression signature associated with survival in metastatic melanoma. J. Transl. Med. 4 (2006) 50
49. Critchley-Thorne R.J., et al. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 4 (2007) e176
50. Agostini C., et al. CXC chemokines IP-10 and mig expression and direct migration of pulmonary CD8+/CXCR3+ T cells in the lungs of patients with HIV infection and T-cell alveolitis. Am. J. Respir. Crit. Care Med. 162 (2000) 1466-1473
51. Heller E.A., et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 113 (2006) 2301-2312
52. Szczucinski A., and Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol. Scand. 115 (2007) 137-146
53. Rivino L., et al. Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J. Exp. Med. 200 (2004) 725-735
54. Kobayashi N., et al. Functional and phenotypic analysis of human memory CD8+ T cells expressing CXCR3. J. Leukoc. Biol. 80 (2006) 320-329
55. Sorensen T.L. Targeting the chemokine receptor CXCR3 and its ligand CXCL10 in the central nervous system: potential therapy for inflammatory demyelinating disease?. Curr. Neurovasc. Res. 1 (2004) 183-190
56. Hancock W.W., et al. Donor-derived IP-10 initiates development of acute allograft rejection. J. Exp. Med. 193 (2001) 975-980
57. Zhang Z., et al. IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection. Gastroenterology 126 (2004) 809-818
58. Schaniel C., et al. Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells. J. Exp. Med. 188 (1998) 451-463
59. Schaniel C., et al. Three chemokines with potential functions in T lymphocyte-independent and -dependent B lymphocyte stimulation. Eur. J. Immunol. 29 (1999) 2934-2947
60. Drayton D.L., et al. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7 (2006) 344-353
61. Harris D.P., et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 1 (2000) 475-482
62. Galon J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
63. Kim S.H., et al. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22 (2005) 131-142
64. Shioya M., et al. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin. Exp. Immunol. 149 (2007) 480-486
65. Cagnard N., et al. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur. Cytokine Netw. 16 (2005) 289-292
66. Shoda H., et al. Rheumatoid Arthritis and Interleukin-32. Cell Mol. Life Sci. 64 (2007) 2671-2679
67. Bigger C.B., et al. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75 (2001) 7059-7066
68. Bigger C.B., et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J. Virol. 78 (2004) 13779-13792
69. Shanker A., et al. CD8 T cell help for innate antitumor immunity. J. Immunol. 179 (2007) 6651-6662
70. Selleri, S. et al. GM-CSF/IL-3/IL-5 receptor common B chain (CD131) as a biomarker of antigen-stimulated CD8+ T cells. J. Transl. Med. (in press)
71. Salazar-Mather T.P., et al. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J. Exp. Med. 187 (1998) 1-14
72. Morris M.A., and Ley K. Trafficking of natural killer cells. Curr. Mol. Med. 4 (2004) 431-438
73. Zhang Q., et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 67 (2007) 10038-10046
74. Chan C.W., et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12 (2006) 207-213